Arming oncolytic viruses with bispecific T cell engagers (BiTEs) for expression and secretion into the tumour microenvironment
<p>Oncolytic viruses exploit the cancer cell phenotype to complete their lytic life cycle, releasing progeny virus to infect nearby cells and repeat the process. We modified the oncolytic group B adenovirus EnAdenotucirev (EnAd) to express bispecific single chain antibodies, secreted from infe...
Main Author: | Freedman, J |
---|---|
Other Authors: | Seymour, L |
Format: | Thesis |
Published: |
2017
|
Similar Items
-
Solid tumor immunotherapy with T cell engager-armed oncolytic viruses
by: Scott, E, et al.
Published: (2017) -
Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer
by: Shiyu Liu, et al.
Published: (2023-09-01) -
Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy
by: Zong Sheng Guo, et al.
Published: (2020-07-01) -
CD3‐T‐cell‐engager (TCE) therapies to overcome solid tumors: Beyond BiTEs
by: Jiali Zhang, et al.
Published: (2022-09-01) -
Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
by: Freedman, J, et al.
Published: (2017)